Unlocking The Potential of BTB Domain-Containing Proteins (G22890)

Target Name: ZBTB1

NCBI ID: G22890

ZBTB1

Unlocking The Potential of BTB Domain-Containing Proteins

ZBTB1, also known as Zinc finger and BTB domain-containing protein 1, is a protein that is expressed in a wide range of tissues and cells in the human body. It is a member of the BTB domain family, which is a family of proteins that contain a zinc finger and a short N-terminal extension. ZBTB1 is unique among its family members because it is able to form a complex with the protein tyrosine kinase (TK) in the cytoplasm. This interaction between ZBTB1 and TK suggests that the protein may play a role in the regulation of cell signaling pathways.

One of the key functions of ZBTB1 is its ability to regulate the activity of TK. TK is a protein that plays a role in cell signaling by activating the MAPK/ERK signaling pathway. This pathway is involved in a wide range of cellular processes, including cell growth, differentiation, and survival. ZBTB1 has been shown to inhibit the activity of TK, which would normally activate the MAPK/ERK pathway. This inhibition of TK activity is important for the regulation of cell growth and the maintenance of tissue homeostasis.

Another function of ZBTB1 is its role in the regulation of cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs. ZBTB1 is involved in the regulation of cell adhesion by interacting with the protein cadherin. This interaction between ZBTB1 and cadherin allows the protein to regulate the activity of cadherin, which is involved in cell adhesion.

In addition to its role in cell signaling and adhesion, ZBTB1 is also involved in the regulation of cell cycle progression. The cell cycle is the process by which cells divide and replicate their genetic material. ZBTB1 is involved in the regulation of cell cycle progression by interacting with the protein p21. This interaction between ZBTB1 and p21 allows the protein to regulate the activity of p21, which is involved in the regulation of cell cycle progression.

The ability of ZBTB1 to form a complex with TK and cadherin, as well as its involvement in cell signaling, adhesion, and cycle progression, makes it an attractive drug target. There is ongoing research into the use of small molecules and other compounds to inhibit the activity of ZBTB1 and its downstream targets. These compounds have the potential to be used for the treatment of a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, ZBTB1 is a protein that is involved in a wide range of cellular processes in the human body. Its unique ability to form a complex with TK and cadherin, as well as its role in cell signaling, adhesion, and cycle progression, makes it an attractive drug target. Further research is needed to fully understand the function of ZBTB1 and its potential as a drug target.

Protein Name: Zinc Finger And BTB Domain Containing 1

Functions: Acts as a transcriptional repressor (PubMed:20797634). Represses cAMP-responsive element (CRE)-mediated transcriptional activation (PubMed:21706167). In addition, has a role in translesion DNA synthesis. Requires for UV-inducible RAD18 loading, PCNA monoubiquitination, POLH recruitment to replication factories and efficient translesion DNA synthesis (PubMed:24657165). Plays a key role in the transcriptional regulation of T lymphocyte development (By similarity)

The "ZBTB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZBTB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets